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ABSTRACT 
Background: Familial Hypercholesterolaemia (FH), an inherited lipid disorder causing 
premature heart disease, is severely underdiagnosed.  
Aim: To evaluated the accuracy of a clinical tool (FAMCAT) for identifying FH in primary 
care.  
Design and setting: Retrospective cohort study of 1,030,183 patients, from the UK Royal 
College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database, 
aged over 16 years.  
Method: The FAMCAT algorithm was compared to methods of FH detection recommended 
by national guidelines (Simon-Broome and Dutch Lipid Clinic Score diagnostic criteria and 
cholesterols levels >99th centile). Discrimination and calibration were assessed by area under 
the receiver operating curve (AUC) and comparing observed versus predicted cases. 
Results: 1,707 patients had a diagnosis of FH. FAMCAT showed high levels of 
discrimination (AUC 0.844, 95% CI 0.834-0.854), performing significantly better than 
Simon-Broome criteria (AUC 0.730, 95% CI 0.719-0.741), Dutch Lipid Clinic Score (AUC 
0.766, 95% CI 0.755-0.778), and screening cholesterols >99th centile (AUC 0.579, 95% CI 
0.571-0.588). Inclusion of premature myocardial infarction and fitting cholesterol as a 
continuous variable improved the accuracy of FAMCAT (AUC 0.894, 95% CI, 0.885-0.903). 
Conclusion: Better performance of the FAMCAT algorithm, compared to other approaches 
for case-finding of FH in primary care, has been confirmed in a separate population cohort. 
 
 
Keywords: familial hypercholesterolaemia; case-finding; FAMCAT; validation; primary 
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How this fits in 
Many individuals with familial hypercholesterolaemia, an inherited lipid disorder, remain 
undiagnosed globally. This results in lost opportunities to identify and prevent many 
premature heart disease and premature death. This study evaluated the accuracy of a clinical 
tool (FAMCAT) in identifying FH in primary care.  
In this study, FAMCAT has been confirmed to have a better predictive accuracy compared to 
other recommended approaches (Simone Broome criteria, Dutch Lipid Clinic Network 
Criteria and very elevated cholesterol alone) for case-finding FH in primary care.  
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BACKGROUND 
Familial hypercholesterolaemia (FH) is a common inherited cause of raised cholesterol, 
affecting up to 320,000 adults in the UK and 834,000 adults in the US (1 in 250 prevalence 
for the adult general population).[1] Despite internationally recognised guidelines 
recommending clinicians actively identify individuals in primary care settings,[2–4] up to 
80% of individuals with FH are still not identified,[3,5] leading to many avoidable heart 
attacks and early deaths. FH is a condition where preventive interventions to reduce 
premature cardiovascular disease, such as high intensity statins, are highly effective.[6,7] 
Current approaches to clinically predict FH-causing mutation in primary care use the Simon-
Broome diagnostic criteria (SB), Dutch Lipid Clinic Network criteria (DLCN), Make Early 
Diagnosis to Prevent Early Deaths (MEDPED), or total cholesterol over the 99th percentile (> 
7.5 mmol/L under the age of 30; > 9.0 mmol/L over the age of 30).[2,8] The Simon Broome 
criteria,[2] most commonly used in the UK, recommend that individuals with a total 
cholesterol concentration of more than 7·5 mmol/L and a family history of  premature heart 
disease should be classified as having probable familial hypercholesterolaemia in primary 
care and should be referred for further lipid specialist assessment. Patients who then also 
meet specific clinical diagnostic criteria (example, tendon xanthoma), or diagnosis by genetic 
testing, are categorised as having definite familial hypercholesterolaemia. The DLCN 
criteria[9] use a points-based scoring system to classify possible, probable, or definite 
familial hypercholesterolaemia on the basis of differing LDL cholesterol thresholds, family 
history of premature vascular disease and raised cholesterol, personal history of premature 
vascular disease, clinical signs such as tendon xanthoma and arcus senilis, or mutation status. 
MEDPED criteria uses age-stratified total-cholesterol thresholds for both the general 
population and relatives, depending on degree of relation.[10] Identifying patients that fulfil 
these criteria in primary medical care settings usually leads to further specialist assessment 
but may be inefficient given only around 25% of referred patients may be subsequently 
confirmed to have FH.[11,12] The National Institute for Health and Care Excellence (NICE) 
recommended assessment against Simon Broome criteria or Dutch Lipid Clinic Network 
(DLCN) criteria to make a clinical diagnosis of FH in primary care settings.[2] 
A case-finding algorithm, FAMCAT (Familial Hypercholesterolaemia Case Ascertainment 
Tool), has been previously derived and validated using data from almost 3 million primary 
care patients (including over 5,000 cases of FH) from 681 primary care centers in the Clinical 
Practice Research Datalink (CPRD) database.[13] The algorithm had a high predictive 
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accuracy to identify patients with documented FH in primary care – with an area under the 
receiver operating curve (AUC) of 0.86.[13] Area under the receiver operating curve (AUC) 
is an overall measure of the ability of a test to discriminate whether a specific condition is 
present or not present.[14] AUC value lies between 0.5 to 1 where 0.5 denotes a poor 
accuracy and 1 denotes a perfect accuracy. This study aimed to externally validate the 
FAMCAT algorithm in the UK’s Royal College of General Practitioners (RCGP) Research 
and Surveillance Centre (RSC) database, which is a separate database from the CPRD 
database from which the algorithm was originally derived.  
 
 
METHODS 
Study design and population 
Primary care data were extracted from the Royal College of General Practitioners (RCGP) 
Research and Surveillance Centre (RSC) database in the UK (Supplementary Method S1). 
The RCGP RSC sentinel system is the principal primary care public health surveillance data 
used by Public Health England for the UK National Health Service.[15,16] We undertook a 
retrospective cohort study in a large population of primary care patients. This comprised a 
randomly selected sample of adult patients registered for primary medical care from 1st 
January 1999 followed up until 31st January, 2017, who had at least one documented total or 
low-density lipoprotein (LDL) cholesterol measurement (necessary for establishing a 
suspected diagnosis). The cohort comprised all patients who were actively registered and 
contributing data and had visited their family medical practice up until the end date of when 
data were extracted. For patients who were diagnosed with FH, the date of diagnosis was 
specified as their ending date to ensure all predictors remained temporal to their diagnosis. 
Patients less than aged 16 years were excluded from the analysis as cholesterol thresholds for 
diagnosis and treatment of FH in children differ from adults.[2] Patients were also excluded if 
they had a prior FH diagnosis before the study entry date (1st January 1999) or a diagnosis of 
other inherited lipid disorders. 
The starting time point for database interrogation was consistent with the start date used when 
deriving the FAMCAT algorithm (Supplementary Table S1) using CPRD.[13]  
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Outcome 
The primary outcome was defined as the incident diagnosis of FH, identified from a patient 
record, between 1st January 1999 and 31st January 2017. FH is specifically coded in UK 
primary electronic health records (EHRs) using the internationally recognised Read coding 
system. This diagnostic code is entered into primary care electronic records after specialist 
lipid assessment, based on clinical phenotype, and/or by genetic test. 
 
Predictor variables 
FAMCAT was developed as a multivariate logistic regression model, stratified by gender, to 
calculate an individual’s probability of having FH.[13] Box 1 summarises all 10 predictors 
which were incorporated into FAMCAT. Age, cholesterol levels, and triglycerides were 
categorised. Statin potency was determined using classifications based on publication by Law 
et al,[17] incorporated in the most recent UK NICE Lipid Modification Guidelines 
(Supplementary Table S2).[18] Secondary causes of raised cholesterol, such as diabetes and 
chronic kidney disease, were included as predictor variables for lower probability of FH. 
 
Validation of the FAMCAT algorithm with comparator models 
The FAMCAT logistic regression equation developed in the CPRD database was applied 
directly to every patient in the cohort to calculate each patient’s probability of having FH. 
This was done by applying the untransformed regression coefficients and constant term 
provided in Supplemetary Table S1. Descriptive characteristics of study population were 
provided: patient demographics and clinical characteristics. Patients with no data record for 
any clinical variables such as diabetes, chronic kidney disease, and prescribing of statins were 
considered either to not have the condition or not been prescribed the drug. 
Performance of the risk prediction models was assessed by discrimination and calibration 
[19]. Specifically, discriminatory accuracy was assessed for all three models using the area 
under the receiver operating curve (AUC) or Harrell’s c-statistics; with higher values 
representing better discrimination. To generate confidence intervals for the c-statistics, a 
jack-knife procedure[20] was used to estimate standard errors. We also compared the 
discrimination of FAMCAT against Simon-Broome diagnostic criteria,[2] Dutch Lipid Clinic 
Network Score,[9] and a simple classification of total cholesterol above 99th centile [2] (a 
new recommendation made by NICE guideline committee in the latest 2017 update) for 
   
 
7
determining possible FH. Predictors included in the Simon-Broome and Dutch Lipid Clinic 
criteria were extracted using Read clinical classification codes and applied directly to the 
cohort.  
Calibration was defined as how closely the predicted probability of FH agrees with the 
expected probability of FH. This was assessed by plotting the observed number of cases of 
FH against the expected number of cases of FH for each tenth of predicted probability to 
ensure 10 equally sized groups.[21]  
 
Optimisation of the FAMCAT algorithm  
To develop an optimised FAMCAT algorithm, the 10 predictors in the FAMCAT algorithm 
developed from the CPRD database were considered as a priori predictors. History of 
premature atherosclerotic CVD such as coronary heart disease and peripheral vascular 
disease (PVD) have been shown to be significantly associated with FH.[22] These conditions 
related to FH were explored as potential predictors hence included in the model and 
discriminatory performance of the model assessed using AUC. These new predictors included 
a personal history of premature myocardial infarction and history of peripheral vascular 
disease. Cholesterol level was built-in as a continuous variable for these optimised models, 
with an interaction term to specify whether the measurement was a total or LDL-cholesterol.  
The study findings are reported in accordance with the Transparent reporting of a 
multivariable prediction model for individual prognosis or diagnosis (TRIPOD) 
recommendations (Supplementary Table S3). 
 
Patient Involvement 
Involvement of patients and relevant advocate groups at all stages of our previous and current 
related research projects has proved invaluable in helping to further focus study design, 
output and dissemination on the needs of the public and the benefits that can be delivered for 
the community. FH patient representatives for this research project attended study steering 
meetings to advise on study conception and preparation, funding application, review of study 
protocols, and have contributed to interpretation, presentation and dissemination of the 
findings. 
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RESULTS 
Study Population 
From the 1,031,411 patients identified from RCGP database, 1,228 patients were excluded 
due to having other inherited lipid disorder or having all of their cholesterol measurements 
documented after a diagnosis of FH. The cohort of patients included in the analysis 
comprised 1,030,183 (52.1% female) eligible patients from 1 January 1999 to 1st September 
2017. There were 649 men (0.13%) diagnosed with FH compared to 1,058 women (0.2%). 
The baseline age of the cohort was 56 years (SD, 15.3) for men and 57 years (SD, 16.7) for 
women. The mean highest total cholesterol was slightly higher in women at 5.8 mmol/L (SD 
1.3) than in men (5.6 mmol/L; SD 1.2). Table 1 shows the full details of baseline 
characteristics for the entire cohort.  
 
External validation 
Discrimination 
Table 2 shows the discrimination of FAMCAT algorithm compared to other clinical criteria. 
External validation of FAMCAT model in RCGP RSC database showed high level of 
discrimination (AUC 0.844, 95% CI 0.834 to 0.854). The performance of FAMCAT showed 
significantly better discrimination compared to Simon-Broome criteria (AUC 0.730, 95% CI 
0.719 to 0.741) and Dutch Lipid Clinic Score (AUC 0.766, 95% CI 0.755 to 0.778). Figure 1 
shows the receiver operating characteristics curves of the various models.  
Calibration 
The model showed good calibration across all deciles between observed and predicted cases, 
with slight under prediction of cases in the highest two deciles (Figure 2). There was an 
expected sharp increase in observed and predicted cases in the highest deciles of predicted 
probability where 414 cases were observed and 344.8 cases were predicted for the 9th decile, 
and 922 cases observed and 855.3 predicted for the 10th decile.  
Sensitivity and specificity 
A threshold corresponding to the top decile (10th) of predicted probability was used for case-
finding in primary care setting[13] – a probability cut-off of 1/250 or 0.004, the estimated 
prevalence of FH.[3] Using this cut-off, FAMCAT achieved a sensitivity of 77.5% (95% CI, 
75.4% to 79.5%) and specificity of 81.1% (95% CI, 81.0% to 81.2%) with a corresponding 
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positive predictive value of 0.68% (95% CI, 0.64% to 0.71%) and a negative predictive value 
of 100%. 
 
Optimised FAMCAT models 
To optimise the FAMCAT model, cholesterol level was fitted as a continuous variable. 
Predictors considered to be related to FH (that is, personal history of premature MI and 
personal history of peripheral vascular disease) were included, with the risk factors/variables 
from FAMCAT algorithm serving as a priori predictors.  
Fitting cholesterol as a continuous variable and including of personal history of premature MI 
and personal history of peripheral vascular disease, increased model discrimination by 5% 
(AUC 0.894, 95% CI 0.885 to 0.903) when compared to the validation model in the RCGP 
cohort. The optimised model showed good calibration across all deciles between observed 
and predicted cases (Figure 3). There was an expected sharp increase in observed and 
predicted cases in the highest decile of predicted probability where 1285 cases were observed 
and 1100 cases were predicted. 
Using the same threshold corresponding to the top decile (10th) of predicted probability – a 
probability cut-off of 1/250 or 0.004, the optimised FAMCAT model achieved the following: a 
sensitivity of 69.4% (95% CI, 67.2% to 71.6%) and specificity of 92.8% (92.8% to 92.9%) 
with a corresponding positive predictive value of 1.58% (95% CI, 1.49% to 1.67%) and a 
negative predictive value of 100%. The optimised FAMCAT model improved specificity by 
14.4% from the standard FAMCAT model. 
 
 
DISCUSSION 
Summary 
In this study, the FAMCAT algorithm has been validated in a separate cohort of over a 
million patients and has maintained high discriminatory accuracy. This algorithm also 
showed superior performance compared to recomended approaches in UK guidelines for 
case-finding. We have also demonstrated that the predictive accuracy of the FAMCAT 
algorithm can be further improved by incorporating personal history of premature myocardial 
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infarction and peripheral vascular disease and fitting cholesterol levels as a continuous 
variable. 
 
Strengths and limitations 
Our study has a number of strengths, especially the large, population-based sample and a long 
duration of follow-up, to validate and optimise an algorithm which identifies patients with the 
highest probability of existing FH. The RCGP RSC data is is nationally representative of the 
UK primary care patient population, and developed as a national disease and morbidity 
surveillance network. Given this purpose, disease coding and clinical measurements are 
better captured compared to other sources.[16] For instance, the proportion of patients with 
family history of MI recorded (5.7% in men; 6.7% in women) is higher compared to the UK’s 
CPRD database (3.2% for both men and women).[13]  
We acknowledge our study has limitations. The diagnosis of FH in the patient’s electronic 
health records is based on the clinical phenotype, specifically those meeting clinical 
diagnostic criteria following specialist lipid assessment, which may or may not be confirmed 
by genetic testing. However, management of these patients to improve cardiovascular risk, 
will nevertheless be based on clinical phenotype. In UK national guidelines, the key role for 
genetic testing is to activate cascading testing to identify affected relatives by specialist care. 
The diagnosis is based on coded records rather than following an adjudication process which 
would not be feasible in such a large cohort of patients. The use of unadjudicated diagnosis 
coded in records by clinicians, is widely adopted in major clinical epidemiological 
research.[23,24].  
 
Comparison with existing literature 
FAMCAT is the first FH identification algorithm developed for  use in primary care setting. 
Other tools, developed to improve identification of FH in primary care, have incorporated 
DLCN criteria. This includes, tool developed in the SEARCH Study [25], TARB-EX based 
on DLCN and correction for LDL-C [26], and the Caning Tool, an electronic extraction tool 
designed for primary care EHRs based on DLCN [27]. Our previous study [28] and current 
study show FAMCAT has significantly better predictive accuracy for clinical case-finding 
than any of these approaches including MEDPED, in very large primary care populations. 
The higher performance compared to recommended approaches is due to it being developed 
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directly from primary care EHRs. The nature of recording in routine EHRs has its limitations 
hence the application of very specific DLCN criteria developed outside primary care setting 
may not capture the distinict characteristics of individuals who may be at risk. Also, the use 
of blunt categorisations such as TC and family history, or lipid levels alone, capture too many 
individuals who do not have FH. 
 
Implications for research and/or practice 
The current, and previous,[28] external validations of FAMCAT in most general practice 
systems now show it can be confidently applied across UK primary care to identify people 
with possible FH. As with all available approaches, FAMCAT will not identify everyone 
with FH in the general population. Rather, it offers an accurate and practical approach to 
case-find those patients most likely to have FH, so they can be referred for specialist 
assessment and definitive genetic diagnosis (or its exclusion). Other methods such as child-
parent screening or cascade testing in secondary care could further improve identification of 
FH. Our further research is exploring using machine-learning (ML) to identify FH in primary 
care; alongside similar work using secondary care data.[29] 
For clinical practice, the FAMCAT algorithm has been integrated into some GP computer 
systems as an automated case-finding tool – https://www.nottingham.ac.uk/primis/tools/qi-
tools/familial-hypercholesterolaemia.aspx. Although this is available for UK practice, the 
FAMCAT variables are all routinely recorded so the tool could be developed for wider use 
internationally. A web-based FAMCAT online risk calculator is also now available: 
https://prism-uon.shinyapps.io/FAMCAT/.  
In conclusion, this study confirms FAMCAT performs better than other recommended 
approaches to case finding for FH using SB or DLCN criteria or very high cholesterol levels.. 
Use of FAMCAT in general practice will identify those patients with possible FH most likely 
to need referral for specialist diagnosis, and greater intervention to reduce risk of premature 
heart disease.  
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FIGURE TITLES AND LEGENDS 
Figure 1. Receiver operating curves derived from the external validation cohort (n = 
1,030,183) for models of identifying familial hypercholesterolaemia in general practice 
(FAMCAT discrimination compared to recommended diagnostic criteria). Higher area 
under the curve (c-statistic) confers better discrimination 
 
Figure 2. FAMCAT model calibration of observed versus predicted cases of familial 
hypercholesterolaemia in the external validation cohort by deciles of predicted 
probability 
 
Figure 3. Calibration of observed versus predicted cases of Familial 
Hypercholesterolaemia (FH) in the external validation cohort by deciles of predicted 
probability using the optimised FAMCAT model 
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Box 1. Summary of predictor variables in FAMCAT 
 Gender (male/female) 
 Age in years (16-24; 25-34; 35-44; 45-54; 55-64; 65-74; 75-84) 
 Highest cholesterol measurement recorded (mmol/L) 
 Ideal: TC* ≤ 5 OR LDL-C † ≤ 3.3 
 High: TC* > 5 to ≤ 6.5 OR LDL-C* > 3.3 to ≤ 4.1 
 Very High: TC* > 6.5 to ≤ 7.5 OR LDL-C* > 4.1 to ≤ 4.9 
 Extremely High: TC* > 7.5 OR LDL-C* > 4.9 
 Triglycerides within one month of highest cholesterol measurement (mmol/L) 
 Idea: < 1.7 
 Borderline High: ≥ 1.7 to < 2.3 
 High: ≥ 2.3 to < 5.6 
 Very High: ≥ 5.6 
 Not assessed 
 Lipid lowering drugs prescribed within one month of highest cholesterol measurement 
(none; fibrate/bile acid sequestrant/nicotinic acid; low potency statin; medium potency 
statin; high potency statin) 
 Family history of familial hypercholesterolaemia (no; yes) 
 Family history of myocardial infarction (no; yes) 
 Family history of raised cholesterol (no; yes) 
 Type I or Type II diabetes (no; yes) 
 Chronic kidney disease (no; yes) 
     † TC = total cholesterol; LDL-C = low densitiy lipoprotein cholesterol 
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Table 1. Clinical characteristics for the cohort of patients aged 16 years. Values are 
numbers and proportions unless stated otherwise 
Characteristics Men Women 
Total Sample Size 493400 (47.9) 536783 (52.1) 
No (%) diagnosed with familial hypercholesterolaemia 649 (0.13) 1058 (0.2) 
Baseline age years (SD) 56 (15.3) 57 (16.7) 
No (%) with history of coronary heart disease < 60 years 15232 (3.1) 8203 (1.5) 
Ethnicity   
No (%) White 319439 (64.7) 358612 (66.8) 
No (%) Asian 26916 (5.5) 27749 (5.2) 
No (%) Black 14181 (2.9) 17484 (3.3) 
No (%) Mixed 3662 (0.7) 4465 (0.8) 
No (%) Other  4151 (0.8) 4254 (0.8) 
No (%) Unknown 125051 (25.3) 124219 (23.1) 
Lipid Profile   
Highest TC recorded mmol/L (SD)  5.6 (1.2) 5.8 (1.3) 
High LDL cholesterol recorded mmol/L (SD) 3.4 (1.0) 3.5 (1.1) 
Triglycerides during cholesterol measurement mmol/L 
(SD) 
1.6 (1.0) 1.4 (0.8) 
Lipid-lowering drug usage at time of cholesterol 
measurement 
  
No (%) prescribed fibrate, bile acid sequestrant, 
nicotinic acid 
1158 (0.2) 1491 (0.3) 
No (%) prescribed low potency statin 6174 (1.3) 5521 (1.0) 
No (%) prescribed medium potency statin 45510 (9.2) 38948 (7.3) 
No (%) prescribed high potency statin 21860 (4.4) 17183 (3.2) 
Family History   
No (%) with family history of FH 1136 (0.2) 1851 (0.3) 
No (%) with family history of raised cholesterol 6698 (1.4) 10144 (1.9) 
No (%) with family history of myocardial infarction 28213 (5.7) 36175 (6.7) 
Secondary causes of high cholesterol at time of 
cholesterol measurement 
  
No (%) diagnosed with diabetes 84490 (17.1) 68978 (12.9) 
No (%) diagnosed with chronic kidney disease 53866 (10.9) 71332 (13.3) 
Asian includes Indian, Pakistani, Bangladeshi, Chinese and other Asians; FH – familial 
hypercholesterolaemia; LDL – low-density lipoprotein; SD – standard deviation; TC – total 
cholesterol;  
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Table 2. Model discrimination in the external validation cohort for identifying familial 
hypercholesterolaemia in general practice (n = 1,030,183) 
Models 
AUC  
(c-statistic) 
Standard 
Error † 
95% Confidence 
Interval 
FAMCAT 0.844 0.005 0.834 – 0.854 
Simon Broome Criteria ‡ 0.730 0.006 0.719 – 0.741 
Dutch Lipid Clinic Criteria § 0.766 0.006 0.755 – 0.778 
Cholesterol above 99th centile ? 0.579 0.005 0.571 – 0.588 
 
† Jack-knife procedure to estimate standard errors [20] 
‡ Total cholesterol > 7.5 mmol/L or LDL-cholesterol > 4.9 mmol/L + family history of 
premature myocardial infarction [2] 
§ Score based on LDL-cholesterol, family history, clinical history, and physical examination 
[9] 
? The UK National Institute for Health and Care Excellence recommendation of screening for 
FH for cholesterol above 99th centile. That is, total cholesterol > 9.0 mmol/L or LDL-
cholesterol > 6.6 mmol/L if age > 30 years; total cholesterol > 7.5 mmol/L or LDL-
cholesterol > 4.9 mmol/L if age ≤ 30 years [2] 
